SCYNEXIS

SCYNEXIS Working Capital

The Working Capital of SCYNEXIS (SCYX) as of Sep 27, 2026 is 34.87 M USD. In the previous year, Working Capital was 35.26 M USD — a change of -1.10% (lower).

Working Capital

34.87 MUSD

YoY

-1.10%

Last updated:

Working Capital of SCYNEXIS is 2026 34.87 M USD. Working Capital of SCYNEXIS was 2025 35.26 M USD. It decreases by -1.10% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Working Capital of SCYNEXIS is 34.87 M USD in 2026.

Working Capital of SCYNEXIS changed from 35.26 M USD to 34.87 M USD, representing a -1.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — SCYNEXIS

All Key Metrics — SCYNEXIS